HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies BELLUS Health (BLU) Investors of Ongoing Investigation of Possible Securities Fraud, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact the Firm
The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims.
SAN FRANCISCO, July 09, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims. Hagens Berman also encourages persons who may be able to assist the Firm’s investigation to contact its attorneys.
Relevant Holding Period: Before July 6, 2020
Visit: www.hbsslaw.com/investor-fraud/BLU
Contact an Attorney Now: [email protected]
844-916-0895
BELLUS Health (BLU) Investigation:
Hagens Berman’s proprietary investigation focuses on BELLUS’s statements concerning the efficacy of its lead drug candidate, BLU-5937.
BLU-5937, BELLUS’s only drug in clinical trials, treats refractory chronic cough (RCC), a malady impacting millions of patients. Although competing treatments exist, these drugs have an associated side effect of taste loss that has hindered their use. BELLUS promoted BLU-5937 as similarly targeting RCC, but it was specifically designed to reduce the likelihood of taste loss.
But on July 6, 2020, BELLUS shocked investors when it announced that BLU-5937 had missed its mark in its phase 2 clinical trials. The company disclosed that BLU-5937 was not able to outperform placebo when it came to reducing the frequency of cough while patients were awake in its phase 2 study. In response, the price of BELLUS shares crashed over 70% lower.
“We’re focused on investors’ losses and whether BELLUS misled investors about BLU-5937’s viability,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you purchased shares of BELLUS and suffered significant losses, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding BELLUS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 844-916-0895
